Skip to content Skip to footer
Subscribe Now
NEWS

Nanjing Leads Biolabs Reports First Patient Enrolment in P-Ib/II Trial of Opatisumab for Advanced Melanoma

Shots: Nanjing Leads Biolabs has enrolled the first patient in P-Ib/II trial assessing opatisumab as monotx. & in combination with toripalimab, for the treatment of 1L advanced melanoma in China Additionally, Opatisumab is being evaluated as monotx. in a registrational study for EP-NEC that completed enrolment in Aug 2025, & is also under investigation in multiple P-II trials…
4 days ago

Read more

Spotlight Interview_T.J.Sharpe
SPOTLIGHT

Reuters Pharma USA 2025: Pre Conference Talks featuring T.J. Sharpe

With breakthrough discoveries addressing patients' unmet needs, caregivers, decision-makers, and advocacy groups have made great strides towards bringing patient experience to the mainstream.  Today's guest is TJ Sharpe, a Patient Insights Expert and Stage-IV Melanoma survivor. In his topic "Complicating is easy, Simplifying is Difficult, the personalized patient experience", T.J. will shed light on patient…
March 13, 2025

Read more

VIEWPOINTS_Gina Fusaro_2023
VIEWPOINTS

Gina Fusaro, VP, Development Program Lead at BMS Shares her Views on the Acceptance of sBLA by the US FDA and the EMA Validation on MAA for Opdivo

Shots: Gina gave her views on the acceptance of the sBLA by the US FDA and the validation of the Type II Variation Marketing Authorization Application by the EMA for Opdivo as monotherapy for the treatment of patients with completely resected stage IIB or IIC melanoma She also spoke on the epidemiology of melanoma and…
May 16, 2023

Read more